WallStreetZenWallStreetZen

NASDAQ: PTIX
Protagenic Therapeutics Inc Stock Ownership - Who owns Protagenic Therapeutics?

Insider buying vs selling

Have Protagenic Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Alexander K. ArrowChief Financial Officer2022-05-188,000$0.72
$5.76kBuy
Alexander K. ArrowChief Financial Officer2022-05-1723,000$0.71
$16.33kBuy

1 of 1

PTIX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PTIX insiders and whales buy or sell their stock.

PTIX Shareholders

What type of owners hold Protagenic Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc1.37%236,309$81.53kInstitution
Alexander K. Arrow0.88%151,260$52.18kInsider
Geode Capital Management LLC0.60%103,595$35.74kInstitution
Fny Investment Advisers LLC0.43%75,000$25.88kInstitution
State Street Corp0.32%55,246$19.06kInstitution
Citadel Advisors LLC0.14%23,482$8.10kInstitution
Northern Trust Corp0.13%22,485$7.76kInstitution
Warberg Asset Management LLC0.12%20,000$6.90kInstitution
Ubs Group Ag0.10%17,153$5.92kInstitution
Concorde Asset Management LLC0.10%16,718$5.77kInstitution

1 of 2

PTIX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PTIX3.54%0.88%Net Buying
SILO0.69%5.06%Net Buying
OGEN19.83%80.17%Net SellingNet Selling
ARTL4.10%29.20%Net Buying
VLON2.31%14.99%

Protagenic Therapeutics Stock Ownership FAQ

Who owns Protagenic Therapeutics?

Protagenic Therapeutics (NASDAQ: PTIX) is owned by 3.54% institutional shareholders, 0.88% Protagenic Therapeutics insiders, and 95.59% retail investors. Alexander K. Arrow is the largest individual Protagenic Therapeutics shareholder, owning 151,260.00 shares representing 0.88% of the company. Alexander K. Arrow's Protagenic Therapeutics shares are currently valued at $52.18k.

If you're new to stock investing, here's how to buy Protagenic Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.